anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
HAART is considered to be the most effective treatment for HIV. However, sustained and consistent adherence to HAART is necessary for long-term success. Issues such as memory problems, lack of social support, medication side effects, depression, and substance abuse can significantly reduce patient adherence to HAART. This study will evaluate the effectiveness of a managed problem solving strategy to increase HAART adherence in patients with HIV. Both treatment-naive and treatment-experienced participants will be recruited for this study.

The treatment part of this study will last 12 months. Participants will be randomly assigned to receive the managed problem solving intervention or standard of care for 12 months. Participants in the managed problem solving group will have 4 study visits and will receive 3 phone calls for the first 3 months of the study, and 1 phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count. Follow-up phone interviews will be conducted every year for 3 years after the end of treatment.

Study hypothesis: Managed problem solving will result in better adherence to highly active antiretroviral therapy (HAART) and better virologic control and immunological outcomes at the end of 1 year compared with a control group receiving standard or care.
The invention provides application of schizandronic acid to the preparation of medicines for preventing and treating hepatitis virus. The schizandronic acid is a tetracyclic triterpenoid compound. The invention also provides application of schizandronic acid to the preparation of food and health-care products for protecting liver. The invention has the advantages that: the application of the schizandronic acid to the preparation of medicines for resisting hepatitis B virus (HBV) and hepatitis C virus (HCV) is provided for the schizandronic acid serving as the tetracyclic triterpenoid compound. Experiments results discover that the tetracyclic triterpenoid compound has the obvious activity of resisting HBV and HCV, particularly can inhibit the HCV from invading target cells, and can be used for preparing the medicines for resisting the hepatitis B virus and the hepatitis C virus. The invention provides a new source for seeking the medicines for resisting the hepatitis B virus and the hepatitis C virus.
NEW MATERIAL:A peptide expressed by the formula (A is Phe or Tyr; R is -NH2 or -OH) or a salt thereof. USE:A remedy for accessory thyroidal hyperfunction having a property of the N-terminated fragment derivative of the human accessory thyroidal hormone as an antagonist for the accessory thyroidal hormone. PROCESS:Individual amino acids and/or paptide fragments are condensed in the amino acid sequence of the formula to constitute the aimed derivative. In the process, fucntional groups in the side chain or an alpha-amino group in the N-terminated amino acid or both are protected by protecting groups, and the alpha- carboxyl group in the C-terminated amino acid is converted into an amido group when R is -NH2 group and protected by protecting groups when R is -OH group. The protecting groups in the resultant dotriacontapeptide fragment are eliminated by the acid decomposition, e.g. the decomposition with anhydrous hydrogen fluoride, and then purified by the column chromatography with a gel filtration agent and an adsorbent to give the aimed peptide expressed by the formula.
1. Technical Result Increase in the transdermal absorbability of nitroglycerin, simplification of technological process and cheapening of the production cost.            2. Essence A nitroglycerin containing adhesive for the plaster is prepared by the following method: a) in the organic solvent there is conducted radical polymerization of the mixture containing 21-40 weight % vinilacetate, 55-70 weight % C2-8 alkylester of acrylic acid and 3-10 weight % hydroxyalkylester C2-4 of acryl acid introduced into 100 weight % monomer mixture, b) to the organic solvent by stirring is added cross-link binding and nitroglycerin, c) the obtained mixture is heated for its cross-link and binding and for the removal of the solvent the final stage being conducted after applying adhesive on the protective film of the plaster.               3. Field of Application Medicine 2 ind. cl., 6 dep. cl.,  3 fig.
A solid, storage-stable, germicidal, pre-iodine composition comprises in dry admixture with each other a solid oxy-compound of iodine, a solid reducing agent for the oxy-compound of iodine, and a solid desiccant used in amount sufficient to combine during the storage cycle of the composition with ambient and/or endogenous water. The oxy-compounds of iodine are iodic acid, iodine pentoxide, potassium iodate and sodium iodate. Preferred reducing agents are ascorbic acid, dihydroxy fumaric acid, the thiol sugars and cysteine. A preferred combination desiccant and iodine solvating agent is polyvinyl pyrrollidone having a molecular weight of from 10,000 to 1,000,000. The composition is storage-stable for an indefinite period. Upon the addition of water, the oxy-compound of iodine is reduced to nascent iodine, which, in application, serves its well-known germicidal function.
Porous implantable devices for housing one or more therapeutic agents are disclosed herein. The implantable devices include a porous outer wall defining an interia or void. The interior void houses a carrier material carrying a first therapeutic agent. The implantable devices are made by patterning at least a portion of a polymerizable substrate into a polymerized three-dimensional porous outer wall surrounding an interior void. This can be achieved by two-photon polymerization techniques. A first therapeutic agent is then added to the interior void, which is then sealed. Methods of treating diseases using the implantable devices are disclosed herein. The methods include implanting the implantable device at a target area and locally releasing a therapeutically effective dosage of a first therapeutic agent from the interior void. The implantable devices can also be used in methods of screening potentially therapeutic agents for desired biological responses.
60 patients,aged 20～60,American Society of Anesthesiologists (ASA) physical status ⅠorⅡ, scheduled for electively lower limb surgery undergoing combined spinal epidural anesthesia were randomly divided three group. In each group,a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia. The initial dose in group 1, group 2 and group 3 was started from 0.9 µg/kg,1.0 µg/kg and 1.1 µg/kg, respectively. HR、MAP、SpO2、the Observer's Assessment of Alertness/Sedation（OAA/S）scale and the corresponding Narcotrend index were recorded at 5-minute intervals until 30 minutes after administration. The relationship between OAA/S scale and Narcotrend index was analyzed by a Spearman analysis. The cutoff values of Narcotrend index for OAA/S≤2 were obtained by analysis of receiver operating characteristic curves(ROC).
Early diagnosis and treatment of PsA may prevent destruction in joints.Our aim is to create a simple and user friendly screening tool that can be used by dermatologists in out patient clinics.

A question pool will be created from a review of the literature and expert opinions from a physicians experienced in rheumatology and dermatologists .Psoriasis patients will answer these newly created questions. All patients will be examined by dermatology and also physical therapy and rehabilitation-rheumatology experts. The diagnosis of psoriatic arthritis (PsA) will be made by CASPAR (Classification criteria for psoriatic arthritis) criteria and ASAS (Assessment of Spondyloarthritis International Society) criteria for spondyloarthritis. Synchronously patients will be asked for to reply Turkish version of well known questionary named TOPAS 2. According to the results of collected data, statistically best matched questions will be selected for Turkish population. Also, the reliability of TUPAST (Turkish PsA Screening Tool) and TOPAS 2 (Toronto Psoriatic Arthritis Screen II) will be compared statistically.
The invention relates to a composition absorbed in intestines and capable of relaxing bowel and expelling toxins. The composition comprises the following components in percentage by mass: 5-95 percent of superfine black fungus powder and 95-5 percent of coconut shell carbon. The invention also provides a preparation method and application of the composition. The composition has the advantages that after the black fungus is subjected to superfine grinding, water in the black fungus can be adsorbed by multiple times, so that the defecate is softened and is conveniently discharged, the coconut shell carbon is not absorbed in the intestines, enterotoxins can be adsorbed, the aim of expelling the toxins is achieved, the combined effects supplement each other, and an optimal effect can be achieved. An enteric coating is coated on the outer layer, so that the product exerts the effects in the intestines and is not damaged by a strongly acidic environment in the stomach, and the best effect is achieved. Moreover, the black fungus powder and coconut shell carbon are taken as raw materials, and the composition is safe in components and non-toxic and harmless to human body.
Estimates derived from National data indicate that seven out of ten residents in assisted living have some form of dementia, with 29% having mild impairment, 23% with moderate impairment, and 19% with severe impairment. More than one-third of these residents display behavioral symptoms commonly associated with dementia, approximately 30-50% experience pain, the majority require assistance with activities of daily living (ADLs) and instrumental activities of daily living (IADLs), are sedentary and have limited opportunities to engage in physical activity. Innovative approaches are needed to help residents with dementia remain in assisted living settings. Typically, however, the care of older adults with dementia living in assisted living settings has followed a "just get it done" approach. The focus of care is on task completion and minimization of behavioral symptoms. This results in care that ignores what the resident is able to do for him or herself and is custodial. Residents are not encouraged to perform activities such as combing their own hair, brushing their teeth, or ambulating. Providing custodial care facilitates a decline in physical capability and function, causes medical complications, exacerbates depressive symptoms, increases the likelihood of sustaining a fall and ultimately may result in a need to be transferred to acute or skilled nursing care. To overcome custodial care we use an approach referred to as Function Focused Care. Function Focused Care is a philosophy of care in which staff members engage residents in physical activity at their highest level of ability during all care interactions. Prior research has repeatedly supported the effectiveness of Function Focused Care in terms of maintaining function and increasing time spent in physical activity among older adults in assisted living settings. We do not know, however, if: (1) there is a difference between those with and without dementia in pain, pain management, behavioral and affective symptoms, or the quality of staff-resident interactions; (2) these factors are associated with participation in function focused care activities at baseline; or (3) there is a differential impact of the Function Focused Care for Assisted Living using the Evidence Integration Triangle Intervention (FFC-AL-EIT) between those with and without dementia in terms of participation in function focused care activities, function and physical activity over the 12 month study period. To answer these questions we propose adding measures for pain, behavioral and affective symptoms and quality of staff-resident interactions to Cohort 2 of the parent study, Testing the Dissemination and Implementation of Function Focused Care (1R01AG050516-01A1). The findings from this study will add to what is currently known about older adults with dementia in assisted living and will be used to revise the FFC-AL-EIT intervention as needed to optimize participation in function focused care activities and thereby maintain and improve function and physical activity among older adults with dementia in assisted living.
PURPOSE: Breast cancer (BC) is heterogeneous in clinical manifestation, of which the triple-negative (TNBC) subtype is the most aggressive. This study examines the associations between Toll-Like Receptor (TLR)-2 polymorphisms and the susceptibility to BC and TNBC.
METHODS: Genotyping of TLR-2 rs1898830 and rs4696483 polymorphisms was done by real-time PCR in 488 women with BC (130 TNBC, 358 non-TNBC) and 476 cancer-free control women.
RESULTS: The minor allele frequency (MAF) of rs4696483 was significantly lower in BC cases compared to controls, and significantly lower frequencies of rs4696483 C/T and higher frequencies of rs1898830 G/G genotypes were seen in BC cases. Significantly higher MAF of rs4696483 and higher C/T and T/T rs4696483 genotypes frequencies were seen in TNBC than in non-TNBC cases. Considering the prevalent AC haplotype as a reference, 2-locus TLR-2 haplotype analysis did not identify any 2-locus TLR-2 haplotype associated with an altered risk of BC or TNBC. Positive associations of rs1898830 and rs4966483 were seen with the histological type in TNBC and negatively with distant metastasis and HR status in TNBC and non-TNBC rs1898830 carriers. In addition, rs4696483 was positively correlated with hormonotherapy and surgery in non-TNBC cases, while rs1898830 was negatively associated with hormonotherapy. Furthermore, rs1898830 was negatively and positively correlated with BMI in TNBC and TNBC cases, respectively, but positively with Ki-67 status.
CONCLUSIONS: Our study highlights the association between TLR-2 genetic polymorphisms and BC and TNBC susceptibility, suggesting these variants' diagnostic/prognostic capacity in BC patients and patient subgroups.
The present disclosure provides a safe method for opioid abuse deterrence, anesthesia or the treatment of pain by safely administering an amount of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure provides a pharmaceutical composition comprising a therapeutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory suppressants by combining a chemoreceptor respiratory stimulant with an opioid receptor agonist or other respiratory-depressing drug. The combination of the two chemical agents, that is, the therapeutic agent and the respiratory stimulant, may be herein described as the "drugs." The present compositions may be used to treat acute and chronic pain, sleep apnea, and other conditions, leaving only non-lethal side effects. When the novel pain medication contains doxapram and an opioid, it can also be used as an opioid abuse deterrent. In particular, this formulation is useful when formulated for oral or transdermal delivery.
BACKGROUND: Hypomyelinating leukodystrophy-9 (HLD-9) is caused by biallelic pathogenic variants in RARS1, which codes for the cytoplasmic tRNA synthetase for arginine (ArgRS). This study aims to evaluate the clinical, neuroradiological, and genetic characteristics of patients with RARS1-related disease and determine probable genotype-phenotype relationships.
METHODS: We identified three patients with RARS1 homozygous pathogenic variants. Furthermore, we performed a comprehensive review of the literature.
RESULTS: Homozygous variants of RARS1 (c.2T>C (p.Met1Thr)) were identified in three patients with HLD-9. Clinical symptoms were severe in all patients. Following the literature review, thirty HLD-9 cases from eight studies were found. The 33 patients' main symptoms were hypomyelination, language delay, and intellectual disability or developmental delay. The mean age of onset for HLD9 in the group of 33 patients with a known age of onset was 5.8 months (SD = 8.1). The interquartile range of age of onset was 0-10 months. Of the 25 variants identified, c.5A>G (p.Asp2Gly) was identified in 11 patients.
CONCLUSION: Pathogenic variants in RARS1 decrease ArgRS activity and cause a wide range of symptoms, from severe, early onset epileptic encephalopathy with brain atrophy to a mild condition with relatively maintained myelination. These symptoms include the classic hypomyelination presentation with nystagmus and spasticity. Furthermore, the pathogenicity of the variation c.2T>C (p.Met1Thr) has been shown.
Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. Doxycycline 150 mg, 100 mg, 75 mg and 50 mg tablets contain doxycycline monohydrate equivalent to 150 mg, 100 mg, 75 mg or 50 mg of doxycycline for oral administration. Inactive ingredients include colloidal silicon dioxide, FD&C yellow #6, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, and titanium dioxide. In addition, doxycycline 100 mg and 50 mg tablets contain hypromellose 3cP, hypromellose 6cP, D&C yellow #10 lake, polyethylene glycol 400, polysorbate 80; doxycycline 150 mg and 75 mg tablets contain hypromellose, lactose monohydrate, synthetic yellow iron oxide and triethyl citrate. Its molecular weight is 462.46. The chemical designation of the light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline.

Structural formula:

C 22H24N2O8•H2O 

Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.
Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for patients with acute ST-segment elevation myocardial infarction (STEMI). Additional anticoagulation therapy prior or during intervention plays an important role in the short- and long-term outcomes after PPCI. Two separate studies have shown significant benefit against conventional therapy based on clopidogrel and heparin for two recently approved drugs: the direct thrombin inhibitor bivalirudin and the thienopyridine prasugrel. In the HORIZONS-AMI trial, bivalirudin after pretreatment with clopidogrel resulted in improved net clinical outcomes. However, during the first 24 hours after PPCI an increase in the stent thrombosis rate was observed with bivalirudin therapy. Prasugrel has been shown to be superior to clopidogrel in patients with acute coronary syndromes undergoing PCI. The benefit in reduction of ischemic complication was even greater in the subset of patients with STEMI without any increase in the bleeding risk and with a significant reduction in the stent thrombosis rate. Expectedly, the synergic actions of prasugrel and bivalirudin may maximize the benefit of antithrombotic therapy for STEMI patients undergoing PPCI.
Virginal gigantomastia (VGM) is a benign disease of the breasts without a clearly established etiology. The treatment of VGM remains a problem. The conservative treatment is not effective while surgery is too traumatic. Most specialists recommend subcutaneous mastectomy with immediate implant reconstruction or reduction mammoplasty. The reduction mammoplasty with adjuvant hormone therapy is a variant of treatment of young patients with a risk of recurrence. We present a case of a patient with VGM who was operated in 2014. Reduction mammoplasty was performed. After 9 years, the patient had a relapse and second surgery, resection of the breasts with reduction mammoplasty. Tissues with cysts, fibrosis, hamartomas, and fibroadenomas were dissected. Histopathology revealed extensive fibrosis with hamartomas and fibroadenomas. The immunohistochemical examination of the breast tissue showed a high level (70%) of estrogen and progesterone receptors expression. We prescribed hormone therapy with tamoxifen 10 mg per day. Dynamic monitoring of the treatment result and control of the disease remission was carried out. Breast-conserving surgery performed in such patients can help alleviate the psychological, social, and physical disorders caused by VGM.
PURPOSE:An antimetastatic agent for cancer containing verapamil well known as a remedy for ischemic cardiopathy or a salt thereof. CONSTITUTION:An antimetastatic agent containing verapamil of the formula {chemical name; 5-[( 3,4-dimethoxyphenethyl)methylamino ]-2-(3,4-dimethoxyphenyl)-2-isopropyl valeronitrile} or a salt thereof as an active constituent. In the case of death of cancer, the metastasis is often a cause therefor. The prevention and treatment of cancer metastasis are very important for reducing the mortality rate of the cancer. The compound of the formula has been recently found to inhibit remarkably the cancer metastasis in many cancer metastasis experiment systems of animal experiments and to be useful as the antimetastatic agent. The dose thereof is usually 10-500mg/day orally or parenterally administered.
These adverse reactions have been reported in approximately 50% of treated patients. They consist of erythema, rash, striae, vesiculation, hyperpigmentation, and tenderness of the skin. Hyperkeratosis, nail changes, alopecia, pruritus, and stomatitis have also been reported. It was necessary to discontinue bleomycin therapy in 2% of treated patients because of these toxicities.

Scleroderma-like skin changes have been reported.

Skin toxicity is a relatively late manifestation usually developing in the second and third week of treatment after 150 to 200 units of bleomycin have been administered and appears to be related to the cumulative dose.

Intrapleural administration of bleomycin has been associated with local pain. Hypotension possibly requiring symptomatic treatment has been reported. Death has been reported in association with bleomycin pleurodesis in seriously ill patients.
Immuno- and targeted therapies have shown promising results for many types of cancer (1). However, the effectiveness of these treatments is not optimal for many patients (2). Therefore, further research is needed to discover, define, and develop genomic, transcriptomic, and integrated molecular markers that can improve clinical outcomes across cancer types (3). Unfortunately, current research is restricted by the limited availability of genomic and transcriptomic results linked to clinical outcomes (3). This study will allow for the collection of key clinical data, including longitudinal follow-up, linked with individual genetic and molecular findings in a single comprehensive registry-based databank. Analysis of these data may lead to advances across cancer subtypes through the identification of transcriptomic and genomic associations with therapies.

Clinical and pathological information, including detailed genetic information from a participant's tumor biopsy, will be obtained by the research staff for each participant enrolled in the BIGR Study. Clinical information will include relevant details about the patient's diagnosis and treatment and will be stored in a secure electronic registry database. No extra scans or procedures for this study will be collected as part of this study. Information will be collected regarding a participant's initial diagnosis, treatment, and outcome. To obtain this information, study staff will contact participants or a participant's doctor at regular time intervals for up to 15 years.